Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
Prithwish has close to 28 years of experience in a Commercial role
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Subscribe To Our Newsletter & Stay Updated
